RESEARCH PAPER

Sustainable Quality Systems in Pharmaceutical Industries: Waste Reduction While Ensuring Compliance

Lokesh Vishwa[1], C Sowmya[2] and K Sujatha[3]*

[1]Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Porur – 600116, Chennai, Tamil Nadu.
[2]Department of Pharmaceutics, Sri Ramachandra Faculty of PharmacySri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Porur – 600116, Chennai, Tamil Nadu.
**[3]Principal and Professor, Department of Pharmaceutical Chemistry, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (DU), Porur – 600116, Chennai, Tamil Nadu.*
*[2]Email: drcsowmya@sriramachandra.edu.in and *[3]Email: Sujatha.k@sriramachandra.edu.in*

Received: 28th Feb, 2026; Revised: 6th March 2026; Accepted: 7th April, 2026; Available Online: 20th April, 2026

ABSTRACT
The pharmaceutical business still faces challenges in balancing sustainable waste-reduction methods with high-quality standards. This article reviews the role of sustainable quality systems and their application in drug product manufacturing in a compliant manner. Key aspects of GM – QMS, PQS, GMP and QA/QC are reviewed in terms of their environmental impact and performance. This paper draws the waste generation of expired drugs, overproduction from synthesis process, packaging and residue chemicals or biologicals also e-waste to boost pollution as well resource loss and carbon gases. Various existing waste-reduction technologies, including lean manufacturing, green chemistry, solvent recovery, digital waste monitoring, circular supply chain and resilient wastewater treatment, are presented as major techniques to prevent environmental load and mitigate risks to public health. However, there are still obstacles that hamper the adoption throughout the industry, such as a fragmented regulation landscape which is butchy in terms of countries or economies rather than uniform and the amount of investment required to install AMTs in commercial environments as well as management resistance and the risk-averse quality culture. Smaller companies are also relatively more resource-constrained than larger innovator companies. The governance of such policy coherence, upscaling emerging technologies and the instigation of a culture of green organisations are crucial for expediting the transition towards sustainable pharma production there by contributing to better health equity across different populations and regions.

Keywords: *Sustainable Quality Systems, Pharmaceutical Waste Management, Regulatory Compliance, Pollution, Circular Supply Chains, Public health.*
How to cite this article: Vishwa L, C Sowmya and K Sujatha, Sustainable Quality Systems in Pharmaceutical Industries: Waste Reduction While Ensuring Compliance. Int J Drug Deliv Technol. 2026;16(68s):1275-1281 DOI: 10.25258/ijddt.16.68s.149
Source of support: Nil.
Conflict of interest: None

INTRODUCTION

Healthy quality systems that fit in with sustainable development have become a critical research area in the pharmaceutical industry today. Because that industry has an immense environmental footprint and is subject to strict regulation, pressure for reflection on these problems only grows heavier. Technologies for green pharmaceutical industry production, such as chemotherapy, immunotherapy, and biotechnology which are also the themes Dominique Dutscher takes up in this report on Asia largest cancer center: National Taiwan University Hospital in Taipei The pharmaceutical industry has moved from traditional manufacturing to incorporate green chemistry and lean manufacturing practices in order to reduce waste and emissions while maintaining the quality of products.(1,2). In recent years, sustainability principles have come to be accepted by people. This is due in part to worldwide market size growth and increased global environmental concern. For example, the number of pharmaceutical recalls and wastes produced has surged in recent years. The former are notorious for costing hundreds of millions of dollars to settle alone as well as contributing to inefficiencies within your entire supply chain (5,6). This is evidence in both professional circles and in academic research that it is possible to achieve a practical system of quality assurance, and one which gives full heed to environmental ethics as well.(7,8)

In spire of the concentration on QA and compliance still going on today in large numbers of companies, however, there exist two marketiza setaesware materials which cannot be made from reused particles these include drug tablets and the scorched earth agent di-hydrogen monoxide (otherwise known as acids). But if nothing is changed then

**Author for Correspondence: Sujatha.k@sriramachandra.edu.in*

hydrogen peroxide which comes as a by-product (9,10). One of the major lack of knowledge todate seems to be that at the cross point between quality management due to waste treatment technology. Specifically, how can a lean manufacturing approach and new waste treatment process technology be applied to current regulatory requirements? (11). There are some debates around issues like, is it financially possible to implement ZLD as opposed to just doing a piece of that work (about 12), At the same time, it involves the contradiction on various systems of quality control strictness and environmental protection trade-off. Failure to close this gap would lead to increasing environmental pollution, more serious economic loss as well as trust (13).

Concepts and methodological framework of research on green quality systems and environment protection, rubbish reduction: Remedial methodology in traditional manufacturing processes (such as iron refining or steel making)--and regulatory compliance has been pieced together from official prescription manuals and classic venous medicine literature of the Song Dynasty. This review article uses this to construct such a conceptual framework comprising sustainable quality systems, waste reduction and regulatory requirements in pharmaceutical production. Sustainable quality systems refer to integrated management methods that ensure both product safety and efficacy, while minimizing their impact on the environment (14,15). Waste reduction consists of lean manufacturing, green chemistry and advanced waste treatment technology aimed at minimizing environmental pollution (2,16). Regulatory compliance entails using Good Manufacturing Practices as well as environmental legislation instead to ensure that pharmaceuticals are made legally(17).

In a systematic review, a team headed by Dr. J.K. Woods regarded the current sustainable practices of quality systems in pharmaceutical industry. Emphasis is heavily placed on the reduction methods which will lend a clean record, and such can be applied equally across the board in any other field having an interest is waste. The work attempts to respond to the integration demand in knowledge and technology areas and technological innovation environments. It seeks to address this deficiency through a systematic cross-disciplinary focus, tending down the pathways of invention and novelty (New Innovations) as much as on method (methods), seeking out challenges in their inception. The review represents an important contribution to the sustainability literature for pharmaceuticals, as it attempts to give a full account of what being joined up between sustain-ability and quality assurance might look like in practice.

Overview on quality system

Drug manufacturers quality systems are paramount to be widely accepted in the pharmaceutical industry, so that drugs can meet safety, efficacy and quality standards. A system of quality is made up of a thousand factors - including a complex network of processes and requirements (13) that govern the entire existence (or "life cycle") of a drug product Cradle to Grave. While I say this its Mosby's Medical Dictionary (8th Edition-2009) that reinforces this. To lead the production sites at an acceptable level, a proper(QMS)must be introduced. This standard is internationally accepted. It promotes international trade and enhances our competitive ability by becoming more efficient. The main characteristics in pharmaceutical quality systems and methods are summarised hereafter.

Quality Management Systems (QMS)

The management system is a formal arrangement which guarantees that the products produced meet quality standards only in, as much as getting a process to right and keep improve. It involves such things as assessing the market patient's requirements; formulating a recipe (a formula) for these requirements and then devising methods of preparation which will meet product specifications(18).

In order to preserve product identity, purity, and quality, the QMS must adhere to international standards like Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP). (19)

Pharmaceutical Quality Systems (PQS)

The PQS stretches from product development over production to phase out. It incorporates GMP and Quality Risk Management concepts as described by the ICH (The International Council on Harmonisation).

Support for the PQS is found in various official pharmacopeias including USP and EP that give standardized specifications to quality control (20)

Quality Assurance and Control

Internal (Butt on 1992) and external audits are used to ensure compliance with GMP and GLP(21)

Quality control labs are at the center of drugs-making, relying on accuracy tools of analytical chemistry and delivering consistent date for research and development efforts. (22)

The function of a pharmaceutical Quality System, on the other hand is to design and implement prevention measure which will help assure that pharmaceutical products are safe and effective. At the same time as this primary goal, they also focus significantly on meeting international standards that will enable greater international trade. This global vision is quite vital for any pharmaceutical company still expanding into the market and wanting to secure an even stronger edge in its competitive environment-output

Effect of pharmaceuticals on the environment and human health:

UNESCO lists human pharmaceuticals as one of the emerging contaminants. It is very important because their detection and elimination represents a crucial step in implementing the "2030 Agenda for Sustainable Development" Goal Targets (UNESCO 2020)(23).However, drugs concentrations in the environment are orders of magnitude below therapeutic

levels. We find pharmaceuticals in water bodies cleaner than rain, with levels not exceeding 100 ng/L. Under these conditions, their toxic effects on human health and the environment are hard to ascertain. Most drugs have not been examined for their long-term harmful effects, occurrence in nature or fate within the environment.

Then again, certain pharmaceutical groups had also been found in scientific studies to severely damage ecology: beta-blockers, antibiotics, anticancer drugs and others interfered with the ecosystem's operation for example increase of mortality rate among fish or snails impaired physiological ability such as swimming non-stop reproduction cycle means work takes too much energy to keep up all important information carefully hidden "Very slowly and patiently they start to extract information from animals by stealth" There are catastrophic health effects for people as well. Every living creature on the planet is connected in some way or other. Moreover, human beings are directly dependent upon Nature. When put into context: the vast number of drugs they posses, and related programmatic difficulties in assessing risk associated with exposure to many compounds at low doses and over long spans all unidentified times -- this is still largely uninvestigated territory overall. The German Environment Agency (UBA), says ten percent of all drugs in commerce might be environmentally unfriendly.Reports say certain pharmaceuticals are widely used and have been shown to carry again negative effects for ecosystems, even though we have not had the means to measure them all with sufficient precision until now. These include beta-blockers; anti-inflammatory painkillers; antidepressants and anti-anxiety drugs; hormones such as contraceptives or antibiotics; cancer-fighting medicine.(24)

Types of Waste Generation in the Pharmaceutical Industry

In addition to mankind itself being seen as endangered for first time, the pharmaceutical industry's production, consumption and academic research involves waste of both kainic and non kainic type. Along the chain of speckle points from which they arise, these waste takes all shapes most are solid, some as liquid others gaseous, material-based or virtual. They not only pose problems related to legislation and regulation, but also add to our environmental burdens such greenhouse gas emissions water pollution or land being loaded with those type masses which is politically incorrect nowadays.



1. Expired and Unused Medications

A major amount of pharmaceutical waste occurs when medicines become obsolete before anyone has taken them.

This phenomenon is particularly prevalent in hospitals, pharmacies, and warehouses. In order to prevent stock running out, inventory levels are often too high.

Note that surplus stock expiring adds significantly to global pharmaceutical waste for medicines that cannot be legally or safely given new expiry dates.

These expired goods in the end have to be disposed of in ways that consume energy, such as through incineration, causing further environmental damage.(25).

2. Overproduction and Excess Inventory

Overproduction: In the pharmaceutical industry, overproduction often means making more drugs than the market needs.

As a result, it is the need to give averse clerical error in forecasting, the regulations regarding overage and the desire for guaranteed availability in clinical trials.

In clinical supply chains, then between 50 and 60 per cent of levels can be lost as waste. This discrepancy between planning supply and real consumption

Overproduction, in addition to wasting raw materials and energy,mean that more rubbish has to be thrown away.(26)

3. Inefficiencies in Distribution and Logistics

A further big source of waste can be seen is in the supply chain itself.

Inefficient distribution processes, (e.g. bad transport conditions, late shipments), may lead to products being ruined or abandoned by the time that they reach patients.

If even just a small change in cold chain conditions brings it under these levels then this makes an entire biologic shipment out of use (and wastes it) Temporature-sensitive biologics are particularly fragile and\ \text one moment can

Such waste is illustrative of systemic inefficiencies which may be a major frontier for digital monitoring and predictive analytics in the future.(27)

4. Packaging Waste

Pharmaceutical packaging is an absolute must, without it the medicine is useless, and even if. In the field of drugs, packaging accounts for about 30% of solid waste.At the same time it has been stated elsewhere that plastics, blister packs,shrink wraps and more multi-layered carton originally designed for proof ways of evidence–or for keeping patients safe-and getting used in huge quantities are totally non-recyclableHowever, patient health comes first though the industry is faced with increasing demands to come up with biodegradable, recyclable or less packaging.(25,28)

5. Regulatory and Compliance-Related Waste

Therefore, due to the complexity of drug regulation, duplicate checks often have to be made; resubmissions made concerning documentation rejected; and, sometimes, products themselves thrown out because they are not through local compliance standards of one kind or another.Once again, unreliantly operated units consumed a greater consumption of resources and indirectly brought about increased levels of wastage.Take the situation where a batch produced for one region is found not to meet slightly different packaging or labeling requirements in another. Although in terms of its pharmacological characteristics it may well be fine, we still have to destroy it.(25,29)

6. Chemical and Laboratory Waste

In academic and institutional settings, labs produce a lot of waste. O Nearly all lab toxic chemicals or reagents are thrown away, as a common practice Official report of 1992 student lab tour at University of California, Davis Campus.

Large quantities of solvents used in synthetic chemistry may well escape filtration and precipitate heavy compounds. Can anyone here burn phenolbronze powder onto iron oxide (Fe2O3) powder?" Output from smaller-scale syntheses or experiments.

Then mix them together carefully and add sugar:the sample will undergo a violent reactionImmediately afterwards the compound was shown to be 5-nitropyrimidine; when nitro-yields acetylated formamide Half an hour later that blue quartz madrone hill passed near a 400-foot square deposit of oil that flowed on into the PacificImproper disposal of such materials can lead to contamination of soil and water systems.(26)

7. Biological and Infectious Waste

Biowastes include microbial cultures, contaminated materials, and sharps produced by research labs and even hospital pharmacies.

Gupta and Desai (2024:26--the year combined figures are inclear research was published in early 1996 or later 1999) stress that these kinds of waste pose increased exposures and if left untreated accelerate environmental catastrophe.

Autoclaving, plasma pyrolysis, or incineration are often needed to treat them, and because these methods too consume energy while creating emissions as part of their exhaust products, addtionally use light oil.(30)

8. Electronic and Institutional Waste

With the growing dependence on automation, digitization, and advanced laboratory equipment electronic waste (e-waste) has emerged as a new waste stream.

Fast computers, heavy Servers, old and special stripping devices often contain heavy metals and hazardous components which must be properly handled.(26)

This makes it doubly tough to offset their environmental effects since recycling opportunities remain very limited for custom-built lab equipment.

9. General Non-Hazardous Waste

Thanks to the increasing reliance on automation, digitization, and hi-tech laboratories, electronic waste (e-waste) is a new category of household trash.

Another significant source of general office waste in the pharmaceutical sector may be found in processing and packaging plants.

About 85 per cent of waste from healthcare premises is non-hazardous, but it must be separated out very carefully so as not to be contaminated by other, hazardous streams.

If material is not separated very carefully, you end up with a variety of things burning that could have been recycled.(25)

Together, these categories of waste produce a significant carbon footprint. According to the 2025 study by McGuire and McElhone, pharmaceutical activities account for 52 megatonnes of CO_2 emissions every year. This before anything leaves the company is usually intended for recycling, either directly used by someone at home during another production cycle, sometimes uo-processed for cleaning or purification in accordance with some process

or standard but invariably equivalent to 11 tonnes of waste output with fuel. Most of the loss comes not just through direct waste disposal but also from the wasted energy, raw materials and transportation involved in producing goods that never get used.

Waste Reduction Strategies:
Cutting waste is commonly viewed as crucial for environmental sustainability — aiding harmony with resources and the climate, while protecting the health of people all around. Most recent studies have emphasized that waste management today is particularly crucial in a direct manner for the avoidanc e and reduction of waste at source, not only in terms of handling it after this step. Recently added are process reengineering, material substitution, waste can be recovered, digital optimization and general industry policy interventions. As one whole they present a comprehensive framework for working out how to minimize waste. (30–33)

Source Reduction and Pollution Prevention
The study, as the researchers point out will be source reduction is also recognized to be the most effective component of waste management. They are of the opinion that prevention to be addressed at the source, and this maybe in chemicals management would mean adoption cleaner technologies, use of less hazardous ingredients or use more environmentally sustainable products. These approaches naturally alleviate environmental and public health problems while at the same time reducing human burdens “hostile to” waste supplies.(30)

Valorization of Waste Streams
The volume of landfill we utilize has also been reduced as valorization methods have emerged. Likewise, the investigation of Chauhan et al. (30) It is also reported the biological treatments such as biofertilizer and sugar cane juice to grow energy reproduce from organic wastes. It is another form of waste reduction on a larger scale, not "adding to" trash with the composite building material and low waste to landfills. The thought is not at all lost on academic researchers. Other than that, the other little matter is the fact that with saving resources you also happen to have landfill simply for control. (30)

Digital and Smart Waste Management
There is also an increasing offer of digital tools to enhance the reduction and valorisation of waste. Kumar et al. [3] propose the utilization of IoT systems, smart bins and predictive analytics for collection and separation. These inventions also lower operational waste and transportation emissions while increasing the recycling rate due to the use of real time data management system that automatically adjusts system operation. There does appear to be evidence that digitalisation acts as a primary enabler for consumable savings and productive efficiencies (28)

Industrial Process Redesign and Circular Supply Chains
Highlight the potential scale in the pharmaceutical industry, where process redesign, solvent recycling, and the application of green chemistry can reduce hazardous waste volumes by 60%. It also highlights the role EPR and harmonised regulations can play in “hardwiring” circular behaviour. Supply chain innovations enable industry to reduce both economic cost and environmental impact by incorporating sustainability into their supply chains. (33)

Resilient Wastewater and Treatment Planning
Climate change introduces the waste management into a different perspective. Nolan et al. [5] Modified precipitation and hydrologic patterns may also have greater potential to exceed the capacity of wastewater treatment infrastructure, resulting in discharges of pollutants. They advocate for both robust and flexible wastewater planning in changing climates. These forward-thinking policies will be necessary to maintain waste reduction progress over the long haul.

Regulatory and Organizational Barriers to Sustainable Practices

Regulatory Complexity and Fragmentation
Belal et al. (34) note that broken regulatory structures are still major obstacle to green supply chain integration. Environmental demands are frequently piled on top of safety and efficacy requirements, resulting in overlap, confusion and delay in authorising new products for the market. Also, the competing legislations among geographical areas (environmental risk assessment, prescribing practice and pharmaceutical wastes handling) raises uncertainty and difficulty for compliance. Nikolić et al. (10) also contend that the absence of coordinated environmental policy leads firms not to invest in sustainable innovation out of concern that their new technology may be out-of-sync with eventual policy changes.

High Investment Requirements and Resource Constraints
Transitioning towards sustainability requires significant up-front investments. Belal et al. (34) point out that when compared with the conventional waste conversion processes, investment in greener environmentally friendly manufacturing facilities including solvent recovery and ecologically sound methods results to high initial cost which are not feasible, particularly for small scale or generic manufacturer.

Organizational Inertia and Cultural Barriers
As is well Beyond regulation, organizational culture matters most. Belal et al. (34) note that for many companies, a strong “green culture” is lacking, and efforts toward sustainability tend to be marginalized in the long term due to more immediate financial or regulatory targets. Smale et al. (35) also identify habitual prescribing and dispensing practices as a type of institutional inertia, where there is resistance to move away from standard dosage and packaging although the potential to achieve drug savings exists.

Risk Aversion and Stringent Quality Demands
Further, big pharma is by its very nature risk averse. Belal et al. (34) contend, it may also prevent the ability to explore sustainable alternatives, such as when regulatory pathways are unknown for a new process. Focusing on patient safety is key, but by doing so, environmental concerns often take a backseat, and the rate of green innovation can lag.

Disparities Across Firm Types
Evidence also supports that innovator and biopharmaceutical companies may be more inclined to incorporate sustainability relative to smaller or generic drug manufacturers who find themselves relatively harder pressed in a backdrop of scarcity of resources and weaker regulatory-driven incentives (33,34). That asymmetry threatens to further expand the sustainability gap along the industry and undermine collective momentum to environmental targets.

LIMITATION

Many of the studies are relatively country specific with a concentration on for example, India, Finland and Korea so that findings from these contexts might not be transferable to pharmaceutical companies around the world. The focus on a few states is limited in terms of external validity and may lose regional localisation both for regulations and operations.

A significant number of papers rely on theoretical premises, case studies or qualitative interviews with low numbers of cases, which limits the power and generalisability of findings. This methodological limitation has implications for causal inferences and generalizability.

Most studies also concentrate on one waste stream – whether that be packaging, wastewater or disposal of products all together – and do not consider pharmaceutical waste as a whole. This narrow focus hampers an overview of what strategies of waste reduction there are and how they relate to each other in sustainable systems.

Some of the works address sustainability and regulation separately but do not consider integrated strategies of overall optimisation, where environmental and quality targets are jointly optimised. I Phasing gap: this restricts the application especially for industry, needing an integrated solution.

CONCLUSION

Finally, the review identifies some of the major advances made in different sustainable quality regimes of waste reduction and compliance through technological, managerial and supply chain integration approaches. However, continued difficulties in regulatory complexity – both cost and collaborative governance appear to indicate that a more code active approach is required across all actors if the pharmaceutical trek to full sustainable operations is to be accelerated. Future research should empirically validate holistic frameworks, scale up new technologies and identify efficient policy instruments to narrow the gap between sustainability aspirations and practical implementation ultimately safeguarding public health.

Conflict of interest (COI): None

Funding details: Self-funding

REFERENCES

1. Belal M, SV, & BS. Greening the Pharmaceutical Supply Chain. Business Strategy and The Environment. .
2. Nagadi K (2022). Implementation of green, lean and six sigma operations for sustainable manufacturing. A review. International Journal of Production Management and Engineering, 10(2), 159–171.
3. Bravo AM C de CJ. Insights on Pharmaceutical Sustainable Supply Chains. International Conference on Industrial Engineering and Operations Management 2012:0.
4. Agrawal M, BA, KV, &38; BN (2024). Sustainable pharma: The need, current status and mission for the future. .
5. Bravo AM, & C de CJ (2012). Insights on Pharmaceutical Sustainable Supply Chains. International Conference on Industrial Engineering and Operations Management, 0.
6. McGuire J, & MD (2025). Supply chain waste in the pharma industry. Open Access Government, 45(1), 194–195. .
7. Supriatna A, PET, HOS, SH, & FD (2024). Integrated Management System To Improve Corporate Sustainability Performance The Case Study In The Pharmaceutical Manufacturing Industry. International Journal of Business Society. .
8. Bhadoriya A, PBD, MS, VK, & AP (2024). Materials Sustainability in the Pharmaceutical Industry. Sustainability & Circularity Now.
9. Kharub M (2020). . Integrating the HACCP and SPC for hazard control and process improvement: a case of pharmaceutical industry. International Journal of Pharmaceutical and Healthcare Marketing, 14(4), 561–586.
10. Nikolić B, NN, MA, & MGA (2024). Opportunities for sustainable waste management in the pharmaceutical industry declaration of competing interest. Arhiv Za Farmaciju, 74(6), 832–851. .
11. Shetty P, Sophia S, Shetty Kodialbail V. Zero liquid discharge technology strategies in Indian distilleries and pharmaceutical industries—a paradigm shift toward sustainability. In: Concept of Zero Liquid Discharge. Elsevier; 2023. p. 347–72.
12. Kumar D, MR, & SDP (2024). Innovative Techniques for Pharmaceutical Waste Management:

Enhancing Drug Recovery and Environmental Sustainability. Current Green Chemistry, 12.

13. Hosseini-Motlagh SM, JM, & NN (2021). Coordinating a socially concerned reverse supply chain for pharmaceutical waste management considering government role. Environment, Development and Sustainability, 1–26.
14. Supriatna A, PET, HOS, SH, & FD (2024). Integrated Management System To Improve Corporate Sustainability Performance The Case Study In The Pharmaceutical Manufacturing Industry. International Journal of Business Society.
15. Shu MH, WTC, & HBM (2023). Integrated green-and-quality inspection schemes for green product quality with six-sigma yield assurance and risk management. Quality and Reliability Engineering International. .
16. Elsevier eBooks. Sustainable and eco-friendly treatment of pharmaceuticals wastewater (pp. 329–346). (2023). .
17. Ogugua JO, & EUNL (2024). Strategies for enhancing public health outcomes through sustainable pharmacy supply chain management. 2(2), 012–023. .
18. Bouwman-Boer Y, MAL (2015). Quality Risk Management. In: Bouwman-Boer, Y., Fenton-May, V., Le Brun, P. (eds) Practical Pharmaceutics. Springer, Cham.
19. Authors: Trupti M. Shelar SNJPVCSCD. Quality Management System Volume / Issue: Volume 5, Issue 5, September-October 2023 IJFMR : .
20.: https://www.ema.europa.eu/en/ich-q10-pharmaceutical-quality-system-scientific-guideline.
21. Agarwal S. Quality Assurance: Role in the Pharmaceutical Industry. Scopus Indexed [Internet]. 2023 Sep. 15 [cited 2025 Oct. 5];16(5):6999-7003. .
22. aybishenko B, VR, PG et al. Challenging problems of quality assurance and quality control (QA/QC) of meteorological time series data. Stoch Environ Res Risk Assess 36, 1049–1062 (2022). .
23. Felicia Manole PMGMMANC. A REVIEW OF THE EFFECTS OF PHARMACEUTICAL WASTE ON THE ENVIRONMENT AND HUMAN HEALTH.
24. Aniqa Naseem a LMA b, MAZ b, FAN b, SSJ a, MU a, RS c, NI a. An insight into the impacts of pharmaceutical pollutants on the ecosystem and the potential role of bioremediation in mitigating pharmaceutical pollutants .
25. Jim McGuire and Deborah McElhone (2024). "Supply chain waste in the pharma industry.
26. GUPTA S and SDESAI. “ENVIRONMENTAL IMPACT AND REGULATORY COMPLIANCE: A COMPREHENSIVE APPROACH IN MANAGING INSTITUTIONAL PHARMACEUTICAL WASTE”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 16, no. 6, June 2024, pp. 14-18,.
27. Patel A, & NR (2022). Understanding waste generation hotspots in pharmaceutical operations. Sustainable Chemistry and Engineering, 10(9), 3478–3490.
28. Kumar V, & SM (2023). Solid and liquid waste management in pharmaceutical industries: A systematic review. Environmental Science and Pollution Research, 30(7), 18900–18918. .
29. Botelho A. The impact of regulatory compliance behavior on hazardous waste generation in European private healthcare facilities. Waste Manag Res. 2013 Oct;31(10):996-1001. .
30. Patil GV PK. Biomedical solid waste management in an Indian hospital: a case study. Waste Manag. 2005;25(6):592-9.
31. Shetty SS DDSHSSNPKNSMH. Environmental pollutants and their effects on human health. Heliyon. 2023 Aug 25;9(9):e19496.
32. Erlantz Lizundia O logo ab FL and De. Organic waste valorisation towards circular and sustainable biocomposites bora Puglia.
33. Smart waste management: A paradigm shift enabled by artificial intelligence.
34. Md Mostain Belal VSSB. Greening the Pharmaceutical Supply Chain .
35. Elisabeth M. Smale a EWV b, ERH c d e, TCGE c d, BJF van den B a f, CLB a. Barriers and facilitators to implement the redispensing of unused oral anticancer drugs in clinical care: A hybrid-effectiveness type I study.